SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001072613-19-000286
Filing Date
2019-11-08
Accepted
2019-11-07 21:47:15
Documents
1
Group Members
ANTHONY A. FLORENCE, JR.DAVID M. MOTTFOREST BASKETTNEA 14 GP, LTDNEA PARTNERS 14, L.P.PATRICK J. KERINSPETER J. BARRISPETER W. SONSINISCOTT D. SANDELL

Document Format Files

Seq Description Document Type Size
1 NEW ENTERPRISE ASSOCIATES 14, L.P. - OYSTER POINT PHARMA, INC. 13D oyster13d_18349.htm SC 13D 350207
  Complete submission text file 0001072613-19-000286.txt   352065
Mailing Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093
Business Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 410-842-4000
New Enterprise Associates 14, L.P. (Filed by) CIK: 0001544328 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13D

Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Subject) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91186 | Film No.: 191201916
SIC: 2836 Biological Products, (No Diagnostic Substances)